Verastem, Inc. (VSTM): Price and Financial Metrics

Verastem, Inc. (VSTM): $0.44

0.00 (0.64%)

POWR Rating

Component Grades













Add VSTM to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where VSTM ranks best; there it ranks ahead of 83.3% of US stocks.
  • VSTM's strongest trending metric is Quality; it's been moving up over the last 127 days.
  • VSTM ranks lowest in Momentum; there it ranks in the 3rd percentile.

VSTM Stock Summary

  • With a price/sales ratio of 26.09, VERASTEM INC has a higher such ratio than 95.13% of stocks in our set.
  • With a year-over-year growth in debt of 715.58%, VERASTEM INC's debt growth rate surpasses 97.21% of about US stocks.
  • VERASTEM INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -71.42%, greater than the shareholder yield of only 7.79% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VERASTEM INC are AGLE, PRTC, TGTX, VBLT, and CRBU.
  • Visit VSTM's SEC page to see the company's official filings. To visit the company's web site, go to

VSTM Valuation Summary

  • In comparison to the median Healthcare stock, VSTM's price/sales ratio is 437.5% higher, now standing at 25.8.
  • Over the past 132 months, VSTM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for VSTM.

Stock Date P/S P/B P/E EV/EBIT
VSTM 2022-11-25 25.8 1.3 -1.1 -0.4
VSTM 2022-11-23 26.1 1.3 -1.1 -0.4
VSTM 2022-11-22 25.6 1.3 -1.1 -0.4
VSTM 2022-11-21 26.7 1.3 -1.1 -0.5
VSTM 2022-11-18 27.3 1.4 -1.2 -0.5
VSTM 2022-11-17 26.9 1.3 -1.1 -0.5

VSTM Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 423.83%.
  • The year over year cash and equivalents growth rate now stands at 31.25%.
  • Its 5 year net cashflow from operations growth rate is now at -353.61%.
Over the past 33 months, VSTM's revenue has gone down $14,315,000.

The table below shows VSTM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.141 -56.99 -73.485
2022-06-30 3.143 -52.735 -78.181
2022-03-31 3.643 -53.465 -73.131
2021-12-31 2.053 -53.502 -71.2
2021-09-30 2.014 -65.272 -74.583
2021-06-30 80.659 -9.698 -38.659

VSTM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VSTM has a Quality Grade of C, ranking ahead of 63.22% of graded US stocks.
  • VSTM's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • NERV, BLUE, and OTLC are the stocks whose asset turnover ratios are most correlated with VSTM.

The table below shows VSTM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.015 0.994 -0.646
2021-06-30 0.510 0.602 -0.382
2021-03-31 0.478 0.611 -0.535
2020-12-31 0.455 0.619 -0.911
2020-09-30 0.476 0.624 -1.030
2020-06-30 0.118 0.856 -1.060

VSTM Price Target

For more insight on analysts targets of VSTM, see our VSTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.25 Average Broker Recommendation 1.38 (Strong Buy)

VSTM Stock Price Chart Interactive Chart >

Price chart for VSTM

VSTM Price/Volume Stats

Current price $0.44 52-week high $2.62
Prev. close $0.44 52-week low $0.29
Day low $0.41 Volume 602,000
Day high $0.45 Avg. volume 1,879,353
50-day MA $0.47 Dividend yield N/A
200-day MA $1.06 Market Cap 92.06M

Verastem, Inc. (VSTM) Company Bio

Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.

VSTM Latest News Stream

Event/Time News Detail
Loading, please wait...

VSTM Latest Social Stream

Loading social stream, please wait...

View Full VSTM Social Stream

Latest VSTM News From Around the Web

Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021)

Verastem ( NASDAQ:VSTM ) Third Quarter 2022 Results Key Financial Results Net loss: US$18.1m (loss narrowed by 21% from...

Yahoo | November 8, 2022

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON, November 03, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.

Yahoo | November 3, 2022

Verastem Oncology Appoints Anil Kapur to Board of Directors

BOSTON, October 20, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022. Mr. Kapur is the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation.

Yahoo | October 20, 2022

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, October 07, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 22,500 shares of its common stock and the grant of 15,000 restricted stock units (RSUs) to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with N

Yahoo | October 7, 2022

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

BOSTON, October 04, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP (Raf And Mek Program) clinical trials.

Yahoo | October 4, 2022

Read More 'VSTM' Stories Here

VSTM Price Returns

1-mo 10.36%
3-mo -62.71%
6-mo -63.93%
1-year -81.82%
3-year -67.88%
5-year -88.54%
YTD -78.54%
2021 -3.76%
2020 58.96%
2019 -60.12%
2018 9.45%
2017 174.11%

Continue Researching VSTM

Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:

Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6803 seconds.